BMRA
BIOMERICA (BMRA)
NASDAQ
$2.12-$0.06 (-2.98%)
Price as of Jun 03, 2026 4:10 PM EDT
  • $7.4M
    Market Cap
  • -31.45%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 89
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Biomerica reported Q2 FY2026 results with net sales of $1.21M (down from $1.64M YoY) as the company transitions from legacy products to higher-margin diagnostic offerings. Key developments include a partnership with Henry Schein for inFoods® IBS commercialization, launch of an AI-backed Trigger Food Navigator tool, CMS establishment of a $300 Medicare reimbursement rate for inFoods® IBS, and Egyptian Drug Authority approval of the company's screening test portfolio. Operating expenses declined 4% YoY to $2.96M for the six-month period, and working capital improved by 14.7%.

01/14/2026, 5:17 PM • GlobeNewswire

Biomerica Reports Fiscal 2025 Year End Results

Biomerica reported modest financial performance with $5.3 million in net sales, reduced operating expenses by $1.3 million, and improved operating loss by 19%. The company focused on strategic growth in diagnostic tests, particularly inFoods® IBS, and expanded international market presence.

08/29/2025, 5:12 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$2.17
$2.31
$2.18
1-Year Range
$1.92
$4.14
$2.18
Latest Close$2.18
Change
-$0.18 (-8.26%)
Volume47,643
Market Cap$7.4M
Shares Outstanding3.1M
P/E (TTM)4.98
Diluted EPS (TTM)$0.48
Enterprise Value$6.0M

Information as of 06/02/2026

Company Profile

$7.4M
Market Cap
-$4.2M
Net Income
Sector: Healthcare
Industry: Medical Devices
17571 Von Karman Avenue, Irvine, CA, United States, 92614
949 645 2111

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Key Executives

  • Gary Lu
  • Zackary S. Irani
  • Allen C. Barbieri
  • Scott Madel
  • Lucy Liu

Current Ownership Distribution

  • Institutions41.9M (71.51%)
  • Mutual Funds13.4M (22.92%)
  • Insiders3.3M (5.57%)
  • Other0 (0.00%)